H2A.Z histone variants facilitate HDACi-dependent removal of H3.3K27M mutant protein in pediatric high-grade glioma cells
Cell Reports · 2024
DOI: 10.1016/j.celrep.2024.113707 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2024. Verfasst von Katarzyna B Leszczynska und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Warsaw, Poland. Electronic address: k.leszczynska@nencki.edu.pl. Hauptthemen laut MEDLINE: Glioma, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Diffuse intrinsic pontine gliomas (DIPGs) are deadly pediatric brain tumors, non-resectable due to brainstem localization and diffusive growth. Over 80% of DIPGs harbor a mutation in histone 3 (H3.3 or H3.1) resulting in a lysine-to-methionine substitution (H3K27M). Patients with DIPG have a dismal prognosis with no effective therapy. We show that histone deacetylase (HDAC) inhibitors lead to a significant reduction in the H3.3K27M protein (up to 80%) in multiple glioma cell lines. We discover that the SB939-mediated H3.3K27M loss is partially blocked by a lysosomal inhibitor, chloroquine. The H3.3K27M loss is facilitated by co-occurrence of H2A.Z, as evidenced by the knockdown of H2A.Z isoforms. Chromatin immunoprecipitation sequencing (ChIP-seq) analysis confirms the occupancy of H3.3K27M and H2A.Z at the same SB939-inducible genes. We discover a mechanism showing that HDAC inhibition in DIPG leads to pharmacological modulation of the oncogenic H3.3K27M protein levels. These findings show the possibility of directly targeting the H3.3K27M oncohistone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Warsaw, Poland. Electronic address: k.leszczynska@nencki.edu.pl.
- Laboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Warsaw, Poland.
- Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, USA.
- Department of Human Genetics, McGill University, Montreal, QC, Canada.
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA; Department of Pediatrics, University Children's Hospital Zürich, Zürich, Switzerland.
- Children's Memorial Health Institute, Warsaw, Poland.
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- NICHD NIH HHS
- Foundation for Polish Science
- National Science Centre Poland
Zitieren
APA
Leszczynska, K. B., Freitas-Huhtamäki, A., Jayaprakash, C., Dzwigonska, M., Vitorino, F. N. L., Horth, C., Wojnicki, K., Gielniewski, B., Szadkowska, P., Kaza, B., Nazarian, J., Ciolkowski, M. K., Trubicka, J., Grajkowska, W., Garcia, B. A., Majewski, J., Kaminska, B., & Mieczkowski, J. (2024). H2A.Z histone variants facilitate HDACi-dependent removal of H3.3K27M mutant protein in pediatric high-grade glioma cells. Cell Reports. https://doi.org/10.1016/j.celrep.2024.113707
Vancouver
Leszczynska KB, Freitas-Huhtamäki A, Jayaprakash C, Dzwigonska M, Vitorino FNL, Horth C, et al. H2A.Z histone variants facilitate HDACi-dependent removal of H3.3K27M mutant protein in pediatric high-grade glioma cells. Cell Reports. 2024. doi:10.1016/j.celrep.2024.113707
BibTeX
@article{Leszczynska2024,
author = {Leszczynska, Katarzyna B and Freitas-Huhtamäki, Amanda and Jayaprakash, Chinchu and Dzwigonska, Monika and Vitorino, Francisca N L and Horth, Cynthia and Wojnicki, Kamil and Gielniewski, Bartlomiej and Szadkowska, Paulina and Kaza, Beata and Nazarian, Javad and Ciolkowski, Maciej K and Trubicka, Joanna and Grajkowska, Wieslawa and Garcia, Benjamin A and Majewski, Jacek and Kaminska, Bozena and Mieczkowski, Jakub},
title = {H2A.Z histone variants facilitate HDACi-dependent removal of H3.3K27M mutant protein in pediatric high-grade glioma cells},
journal = {Cell Reports},
year = {2024},
doi = {10.1016/j.celrep.2024.113707}
}
EUVIMED